Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: MTCH1

Gene summary for MTCH1

Gene summary.

Gene information	Species	Human
	Gene symbol	MTCH1
	Gene ID	23787
	Gene name	mitochondrial carrier 1
	Gene Alias	CGI-64
	Cytomap	6p21.2
	Gene Type	protein-coding
	GO ID	GO:0006508
	UniProtAcc	A0A024RCX4

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23787	MTCH1	HTA11_3410_2000001011	Human	Colorectum	AD	9.95e-07	2.66e-01	0.0155
23787	MTCH1	HTA11_2487_2000001011	Human	Colorectum	SER	7.11e-06	3.87e-01	-0.1808
23787	MTCH1	HTA11_1938_2000001011	Human	Colorectum	AD	2.15e-10	5.84e-01	-0.0811
23787	MTCH1	HTA11_78_2000001011	Human	Colorectum	AD	4.27e-08	4.51e-01	-0.1088
23787	MTCH1	HTA11_347_2000001011	Human	Colorectum	AD	1.13e-19	5.36e-01	-0.1954
23787	MTCH1	HTA11_411_2000001011	Human	Colorectum	SER	6.17e-08	1.00e+00	-0.2602
23787	MTCH1	HTA11_3361_2000001011	Human	Colorectum	AD	2.71e-10	5.78e-01	-0.1207
23787	MTCH1	HTA11_83_2000001011	Human	Colorectum	SER	2.36e-04	3.48e-01	-0.1526
23787	MTCH1	HTA11_696_2000001011	Human	Colorectum	AD	8.22e-16	5.95e-01	-0.1464
23787	MTCH1	HTA11_866_2000001011	Human	Colorectum	AD	3.14e-05	3.64e-01	-0.1001
23787	MTCH1	HTA11_1391_2000001011	Human	Colorectum	AD	6.22e-16	6.46e-01	-0.059
23787	MTCH1	HTA11_2992_2000001011	Human	Colorectum	SER	6.35e-11	7.91e-01	-0.1706
23787	MTCH1	HTA11_5212_2000001011	Human	Colorectum	AD	4.44e-09	6.56e-01	-0.2061
23787	MTCH1	HTA11_5216_2000001011	Human	Colorectum	SER	3.22e-05	5.83e-01	-0.1462
23787	MTCH1	HTA11_546_2000001011	Human	Colorectum	AD	4.01e-03	3.24e-01	-0.0842
23787	MTCH1	HTA11_7862_2000001011	Human	Colorectum	AD	3.28e-05	4.60e-01	-0.0179
23787	MTCH1	HTA11_866_3004761011	Human	Colorectum	AD	3.64e-24	6.91e-01	0.096
23787	MTCH1	HTA11_4255_2000001011	Human	Colorectum	SER	1.37e-03	5.43e-01	0.0446
23787	MTCH1	HTA11_8622_2000001021	Human	Colorectum	SER	1.81e-04	3.99e-01	0.0528
23787	MTCH1	HTA11_7663_2000001011	Human	Colorectum	SER	7.26e-03	4.72e-01	0.0131

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:005254718	Prostate	BPH	regulation of peptidase activity	133/3107	461/18723	2.08e-11	1.43e-09	133
GO:004328118	Prostate	BPH	regulation of cysteine-type endopeptidase activity involved in apoptotic process	71/3107	209/18723	5.88e-10	2.89e-08	71
GO:005254818	Prostate	BPH	regulation of endopeptidase activity	122/3107	432/18723	6.10e-10	2.91e-08	122
GO:200011618	Prostate	BPH	regulation of cysteine-type endopeptidase activity	76/3107	235/18723	1.90e-09	7.79e-08	76
GO:001095218	Prostate	BPH	positive regulation of peptidase activity	66/3107	197/18723	4.44e-09	1.66e-07	66
GO:001095017	Prostate	BPH	positive regulation of endopeptidase activity	56/3107	179/18723	8.24e-07	1.54e-05	56
GO:004328016	Prostate	BPH	positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	43/3107	129/18723	2.41e-06	3.90e-05	43
GO:200105616	Prostate	BPH	positive regulation of cysteine-type endopeptidase activity	46/3107	148/18723	9.21e-06	1.29e-04	46
GO:00069195	Prostate	BPH	activation of cysteine-type endopeptidase activity involved in apoptotic process	24/3107	78/18723	1.39e-03	8.31e-03	24
GO:004586219	Prostate	Tumor	positive regulation of proteolysis	124/3246	372/18723	3.46e-14	4.31e-12	124
GO:005254719	Prostate	Tumor	regulation of peptidase activity	137/3246	461/18723	2.48e-11	1.71e-09	137
GO:004328119	Prostate	Tumor	regulation of cysteine-type endopeptidase activity involved in apoptotic process	74/3246	209/18723	2.29e-10	1.33e-08	74
GO:005254819	Prostate	Tumor	regulation of endopeptidase activity	126/3246	432/18723	5.86e-10	3.01e-08	126
GO:200011619	Prostate	Tumor	regulation of cysteine-type endopeptidase activity	79/3246	235/18723	9.68e-10	4.66e-08	79
GO:001095219	Prostate	Tumor	positive regulation of peptidase activity	68/3246	197/18723	4.09e-09	1.66e-07	68
GO:001095018	Prostate	Tumor	positive regulation of endopeptidase activity	58/3246	179/18723	6.35e-07	1.32e-05	58
GO:004328017	Prostate	Tumor	positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	45/3246	129/18723	1.17e-06	2.21e-05	45
GO:200105617	Prostate	Tumor	positive regulation of cysteine-type endopeptidase activity	48/3246	148/18723	5.51e-06	8.48e-05	48
GO:000691913	Prostate	Tumor	activation of cysteine-type endopeptidase activity involved in apoptotic process	25/3246	78/18723	1.11e-03	7.12e-03	25
GO:004586229	Skin	cSCC	positive regulation of proteolysis	169/4864	372/18723	2.43e-16	2.21e-14	169

Page: 1 2 3 4 5 6 7 8 9 10

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

MTCH1

SNV

Missense_Mutation

c.1070T>C

p.Ile357Thr

p.I357T

Q9NZJ7

protein_coding

tolerated(0.11)

possibly_damaging(0.702)

TCGA-D8-A147-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicine

MTCH1

SNV

Missense_Mutation

c.901N>G

p.Ser301Ala

p.S301A

Q9NZJ7

protein_coding

tolerated_low_confidence(0.12)

benign(0.18)

TCGA-D8-A1Y3-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicine+cyclophosphamide

MTCH1

insertion

Frame_Shift_Ins

novel

c.961_962insCAGTACCAACCTTGGGTTCTCGTGTTCTG

p.Val321AlafsTer11

p.V321Afs*11

Q9NZJ7

protein_coding

TCGA-A7-A0CD-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

MTCH1

SNV

Missense_Mutation

c.182N>T

p.Ser61Leu

p.S61L

Q9NZJ7

protein_coding

deleterious_low_confidence(0.05)

benign(0.025)

TCGA-VS-A958-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

MTCH1

SNV

Missense_Mutation

novel

c.685N>T

p.Arg229Trp

p.R229W

Q9NZJ7

protein_coding

tolerated(0.07)

benign(0.04)

TCGA-AA-3966-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

MTCH1

SNV

Missense_Mutation

novel

c.902C>T

p.Ser301Phe

p.S301F

Q9NZJ7

protein_coding

deleterious_low_confidence(0.01)

possibly_damaging(0.477)

TCGA-AA-A00N-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

MTCH1

SNV

Missense_Mutation

c.1068N>T

p.Trp356Cys

p.W356C

Q9NZJ7

protein_coding

deleterious(0)

possibly_damaging(0.584)

TCGA-DM-A28C-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

MTCH1

SNV

Missense_Mutation

c.1133G>A

p.Arg378His

p.R378H

Q9NZJ7

protein_coding

tolerated(0.06)

benign(0.009)

TCGA-NH-A5IV-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

MTCH1

SNV

Missense_Mutation

novel

c.1072N>T

p.His358Tyr

p.H358Y

Q9NZJ7

protein_coding

deleterious(0.02)

possibly_damaging(0.651)

TCGA-A5-A0G1-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

MTCH1

SNV

Missense_Mutation

c.871G>T

p.Gly291Trp

p.G291W

Q9NZJ7

protein_coding

deleterious_low_confidence(0.01)

benign(0.157)

TCGA-AP-A059-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1